242 related articles for article (PubMed ID: 9059069)
1. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
[TBL] [Abstract][Full Text] [Related]
2. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
Okamoto T; Okada M; Mori A; Saheki K; Takatsuka H; Wada H; Tamura A; Fujimori Y; Takemoto Y; Kanamaru A; Kakishita E
Bone Marrow Transplant; 1997 Nov; 20(9):801-3. PubMed ID: 9384487
[TBL] [Abstract][Full Text] [Related]
4. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
Ehlert K; Groll AH; Kuehn J; Vormoor J
Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
[TBL] [Abstract][Full Text] [Related]
6. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
[TBL] [Abstract][Full Text] [Related]
7. [Ganciclovir-resistant cytomegalovirus infection: 2 cases with different clinical impact].
Reusser P; Hostettler B; Attehbofer R
Schweiz Med Wochenschr; 1996 Oct; 126(42):1779-84. PubMed ID: 8966510
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myelocytic leukemia associated with cytomegalovirus induced sialoadenitis after unrelated allogeneic bone marrow transplantation].
Yoshida M; Ueda S; Harano H; Yamazaki E; Kato K; Tanabe J; Okamoto R; Ogawa K; Mohri H; Okubo T; Sasaki S; Matsuzaki M; Nakatani Y; Chiba N
Rinsho Ketsueki; 1996 Jan; 37(1):46-52. PubMed ID: 8683867
[TBL] [Abstract][Full Text] [Related]
9. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
Takami A; Mochizuki K; Ito S; Sugimori C; Yamashita T; Asakura H; Okumura H; Nakao S
Transplant Proc; 2007; 39(1):237-9. PubMed ID: 17275512
[TBL] [Abstract][Full Text] [Related]
11. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
12. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Moro F; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():110-4. PubMed ID: 8932810
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
15. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Mylonakis E; Kallas WM; Fishman JA
Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
[TBL] [Abstract][Full Text] [Related]
16. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
17. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation.
Kaulfersch W; Urban C; Hauer C; Lackner H; Gamillscheg A; Slavc I; Langmann G
Bone Marrow Transplant; 1989 Sep; 4(5):587-9. PubMed ID: 2551437
[TBL] [Abstract][Full Text] [Related]
19. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation.
Singhal S; Mehta J; Powles R; Treleaven J; Horton C; Carrington D; Tryhorn Y; Jameson B
Bone Marrow Transplant; 1995 May; 15(5):777-81. PubMed ID: 7670405
[TBL] [Abstract][Full Text] [Related]
20. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
